Amgen is one of the world's largest biotechnology companies, discovering, developing, and manufacturing biologic and small-molecule therapies. Its portfolio spans general medicine, including cholesterol-lowering Repatha and osteoporosis treatments Prolia and EVENITY; inflammation, with Otezla, Enbrel, and biosimilars; oncology, including BiTE therapy Blincyto, KRAS inhibitor Lumakras, and Vectibix; and rare diseases, substantially expanded by the 2023 acquisition of Horizon Therapeutics, which added thyroid eye disease treatment Tepezza, gout therapy Krystexxa, and Uplizna. Amgen is developing MariTide, an obesity therapy, in one of its highest-profile pipeline programs, and operates a leading biosimilars business. Founded in 1980, a pioneer of the biotechnology industry, Amgen is headquartered in Thousand Oaks, California, and markets in approximately 100 countries.

Piotroski F-Score

Beneish M-Score

Revenue per Share

Gross Margin %

Insider Sell

Operating Margin %

Price

PS Ratio

Dividend Yield %

Altman Z-Score

Amgen Inc